Cardiac tumors screening
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors screening On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors screening |
|
Risk calculators and risk factors for Cardiac tumors screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Screening
- According to the USPSTF, routine screening for cardiac tumors is not recommended.
- Transthoracic echocardiography (TTE) continues to be the method of choice for screening for cardiac malignancies. Transesophageal echocardiogram (TEE) is commonly used for valvular lesions.[1]
- Emerging technologies such as contrast echocardiography and three-dimensional echocardiogram may substantially improve the diagnostic accuracy of echocardiography.[2]
- The diagnostic accuracy of echocardiography is 80%. After initial diagnosis on TTE, cardiac CT/MRI are commonly used to stage and further evaluate the tumors.[3]
References
- ↑ Lamba G, Frishman WH (2012). "Cardiac and pericardial tumors". Cardiol Rev. 20 (5): 237–52. doi:10.1097/CRD.0b013e31825603e7. PMID 22447042.
- ↑ Mankad R, Herrmann J (2016). "Cardiac tumors: echo assessment". Echo Res Pract. 3 (4): R65–R77. doi:10.1530/ERP-16-0035. PMC 5292983. PMID 27600455.
- ↑ Nomoto N, Tani T, Konda T, Kim K, Kitai T, Ota M; et al. (2017). "Primary and metastatic cardiac tumors: echocardiographic diagnosis, treatment and prognosis in a 15-years single center study". J Cardiothorac Surg. 12 (1): 103. doi:10.1186/s13019-017-0672-7. PMC 5704631. PMID 29183343.